金斯瑞生物科技(01548.HK)：南京蓬勃與禮新醫藥科技有限公司達成許可協議
格隆匯11月15日丨金斯瑞生物科技(01548.HK)發佈公吿，2024年11月12日，公司非全資子公司南京蓬勃生物科技有限公司(“南京蓬勃”)與禮新醫藥科技有限公司(“禮新”)訂立經重述及經修訂許可協議，根據該協議，南京蓬勃同意授予禮新獨家全球可轉讓許可，及其有權授予再許可，使其有權針對若干披露抗 PD-1(細胞程序性死亡因子)單域抗體的專利(“許可專利”)和相關專有技術進行開發、生產、商業化及以其他方式應用若干分子及包含許可分子在內的若干產品(“許可產品”)，以用於全球所有用途。同日， LaNova 就經重述及經修訂協議下(其中包括)的付款安排向蓬勃南京發出確認函，(其中包含)南京蓬勃及鎮江蓬勃生物科技有限公司(公司非全資附屬公司，與南京蓬勃統稱“蓬勃”)將有權根據經重述及經修訂協議從LaNova獲得付款。
根據經重述及經修訂協議及確認函，禮新應在禮新首次發生與許可產品的開發和監管批准相關的各項里程碑事件時向蓬勃支付若干預付款和里程碑付款(取決於相關里程碑事件達成)。蓬勃亦有權從禮新就關於許可的任何再許可實際收到的再許可收益中獲得一定比例的收益。具體而言，(其中包含)就首個開發的授權產品，蓬勃將有權獲得(i) 與在新藥研究申請(IND)批准後但許可產品一期臨牀試驗完成前的任何再許可相關的40%的預付款和25%的其他里程碑付款, 及(ii)禮新所收特許使用費(收入分成)中的25%的。
2024年11月14日，公司注意到默克公司(Merck & Co., Inc.，紐約證券交易所代碼：MRK，其在美國和加拿大以外的地區稱作默沙東(“默克”))發佈了一份新聞稿，稱默克和禮新已訂立獨家全球許可，以開發、生產和商業化 LM-299，這是一種禮新的在研PD-1/VEGF 雙特異性抗體。根據該許可，禮新有權獲得5.88億美元的預付款和高達27億美元的里程碑付款。據公司瞭解，LM-299包含了LaNova 從蓬勃獲得許可的抗PD-1單域抗體。根據新聞稿，(a)擬議交易的完成須根據《哈特-斯科特-羅迪諾反壟斷改進法案》和其他慣例條件獲得批准，(b)該交易預計將於2024年第四季度完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
